Please use this identifier to cite or link to this item:
|Title:||Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway||Authors:||Zhou, J.
|Issue Date:||Jan-2008||Citation:||Zhou, J., Pan, M., Xie, Z., Loh, S.-L., Bi, C., Tai, Y.-C., Lilly, M., Lim, Y.-P., Han, J.-H., Glaser, K.B., Albert, D.H., Davidsen, S.K., Chen, C.-S. (2008-01). Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22 (1) : 138-146. ScholarBank@NUS Repository. https://doi.org/10.1038/sj.leu.2404960||Abstract:||Internal tandem duplications (ITDs) of fms-like tyrosine kinase 3 (FLT3) receptor play an important role in the pathogenesis of acute myeloid leukemia (AML) and represent an attractive therapeutic target. ABT-869 has demonstrated potent effects in AML cells with FLT3-ITDs. Here, we provide further evidence that ABT-869 treatment significantly downregulates cyclins D and E but increases the expression of p21 and p27. ABT-869 induces apoptosis through downregulation of Bcl-xL and upregulation of BAK, BID and BAD. We also evaluate the combinations of ABT-869 and chemotherapy. ABT-869 demonstrates significant sequence-dependent synergism with cytarabine and doxorubicin in cell lines and primary leukemia samples. The optimal combination was validated in MV4-11 xenografts. Low-density array analysis revealed the synergistic interaction involved in downregulation of cell cycle and mitogen-activated protein kinase pathway genes. CCND1 and c-Mos were the most significantly inhibited targets on both transcriptional and translational levels. Treatment with short hairpin RNAs targeting either CCND1 or c-Mos further sensitized MV4-11 cells to ABT-869. These findings suggest that specific pathway genes were further targeted by adding chemotherapy and support the rationale of combination therapy. Thus, a clinical trial using sequence-dependent combination therapy with ABT-869 in AML is warranted.||Source Title:||Leukemia||URI:||http://scholarbank.nus.edu.sg/handle/10635/108562||ISSN:||08876924||DOI:||10.1038/sj.leu.2404960|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 14, 2021
WEB OF SCIENCETM
checked on Jun 14, 2021
checked on Jun 7, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.